Birthweight with Gestation and Maternal Characteristics in Live Births and Stillbirths

Poon, Liona C.; Volpe, N.; Muto, B.; Syngelaki, Argyro; Nicolaides, Kypros H.

doi:10.1159/000338655

Cited by 118 publications

(119 citation statements)

References 67 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…Maternal age at screening was centred at 35 years, maternal weight was centred at 69 kg and maternal height was centred at 164 cm. The z-score is the difference in standard deviations between the observed and expected birth weight for gestational age [19]. Racial origin, method of conception, smoking, family history of diabetes, and previous GDM were treated as categorical variables.…”

Section: Methodsmentioning

confidence: 99%

First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History

et al. 2014

Self Cite

View full text Add to dashboard Cite

Objectives: To develop and validate a prediction model for gestational diabetes mellitus (GDM) at 11-13 weeks' gestation based on maternal characteristics and history and to compare its performance with the method recommended by the National Institute of Health and Care Excellence (NICE) and five other published prediction models. Methods: A predictive logistic regression model for GDM was developed from 1,827 cases (2.4%) who developed GDM and 73,334 unaffected controls. A 5-fold cross-validation study was performed to validate this model and to compare its performance with those of the NICE guidelines and the previously published models. Results: In the logistic regression model, maternal age, weight, height, racial origin, family history of diabetes, use of ovulation drugs, birth weight, and previous history of GDM were found to be significant predictors of GDM. In screening for GDM in the 5-fold cross-validation study, detection rates (DRs) were higher (p < 0.0001) for the proposed model (DR = 83.2%) than for the NICE guidelines (DR = 77.5%) for a false positive rate of approximately 40% (determined by NICE). The area under the receiver operating characteristic curve of the new model was higher (p < 0.0001) than that of the previous five models (0.823 vs. 0.688-786). Conclusions: Early effective screening for GDM can be achieved based on maternal characteristics and history.

show abstract

Section: Methodsmentioning

confidence: 99%

First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…The definition of SGA was birthweight below the 5th percentile of reference range derived from our population [14]. …”

Section: Methodsmentioning

confidence: 99%

Competing Risks Model in Screening for Preeclampsia by Serum Placental Growth Factor and Soluble fms-Like Tyrosine Kinase-1 at 30-33 Weeks' Gestation

et al. 2014

Self Cite

View full text Add to dashboard Cite

Objective: To assess the risk for preeclampsia (PE) by maternal characteristics, serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1)at 30-33 weeks' gestation. Methods: This was a screening study in singleton pregnancies including 2,140 that subsequently developed PE and 83,615 that were unaffected by PE, gestational hypertension or delivery of small-for-gestational-age neonates (normal group). We developed a survival time model for the time of delivery for PE by combination of maternal characteristics and history with PlGF and sFlt-1 multiple of the median (MoM) values (biochemical test). Data on third-trimester PlGF and sFlt-1 were available in 118 cases of PE and 3,734 of normal group. The detection rate (DR) of PE requiring delivery within 4, 6 and 8 weeks of the visit was estimated. Results: In pregnancies with PE, the log₁₀ MoM values of PlGF and sFlt-1 were linearly related to gestational age at delivery. Screening by the biochemical test detected 100, 76, and 62% of PE with delivery within 4, 6 and 8 weeks of the visit, at a fixed false-positive rate of 5%. Interpretation: Testing by PlGF and sFlt-1 at 30-33 weeks could identify all pregnancies developing PE and requiring delivery within the subsequent 4 weeks.

show abstract

“…The definition of SGA was birth weight below the 5th percentile of a reference range derived from our population [11]. …”

Section: Methodsmentioning

confidence: 99%

Prediction of Preeclampsia by Mean Arterial Pressure at 11-13 and 20-24 Weeks' Gestation

et al. 2014

Self Cite

View full text Add to dashboard Cite

Objectives: To assess the performance of screening for preeclampsia (PE) by mean arterial pressure (MAP) at 11-13 and at 20-24 weeks' gestation. Methods: MAP was measured at 11-13 and 20-24 weeks in 17,383 singleton pregnancies, including 70 with early PE, requiring delivery <34 weeks' gestation, 143 with preterm PE, delivering <37 weeks and 537 with total PE. MAP was expressed as multiple of the median (MoM) after adjustment for maternal characteristics and corrected for adverse pregnancy outcomes. The performance of screening for PE by maternal characteristics and MAP MoM at 11-13 weeks (MAP-1), MAP MoM at 20-24 weeks (MAP-2) and their combination was evaluated. Results: In screening by maternal characteristics and MAP-1, at a false-positive rate (FPR) of 10%, the detection rates (DR) of early PE, preterm PE and total PE were 74.3, 62.9 and 49.3%, respectively; the DR at FPR of 5% were 52.9, 42.7 and 35.8%. In screening by MAP-1 and MAP-2 the DR at FPR of 10%, were 84.3, 65.7 and 52.5%; the DR at FPR of 5% were 60.0, 49.7 and 37.6%, respectively. Conclusions: Performance of screening for PE by MAP is best when measurements are taken at both 11-13 and 20-24 weeks' gestation than at only one of these gestational ranges.

show abstract

Birthweight with Gestation and Maternal Characteristics in Live Births and Stillbirths

Cited by 118 publications

References 67 publications

First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History

First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History

Competing Risks Model in Screening for Preeclampsia by Serum Placental Growth Factor and Soluble fms-Like Tyrosine Kinase-1 at 30-33 Weeks' Gestation

Prediction of Preeclampsia by Mean Arterial Pressure at 11-13 and 20-24 Weeks' Gestation

Contact Info

Product

Resources

About